Enzyme Replacement Therapy

Enzyme Replacement Therapy is a treatment where doctors give you a medicine containing a missing or faulty enzyme. This medicine helps your body function better. It's used for certain genetic diseases where the body doesn't make enough of a specific enzyme. The goal is to replace the missing enzyme to ease the symptoms of the disease.

Therapy

What people using Enzyme Replacement Therapy report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Pompe Disease?

NameHow it went

About Enzyme Replacement Therapy

How It Works

Enzyme replacement therapy (ERT) gives the body a manufactured version of an enzyme it cannot make properly. It is used mainly for lysosomal storage diseases, a group of rare inherited conditions caused by a missing enzyme. Lysosomes are the compartments inside cells that break down and recycle fats, sugars and other materials. When one of their enzymes is missing, that material builds up and gradually damages organs such as the liver, spleen, bones, heart, kidneys or muscles, depending on the disease. The replacement enzyme is produced in cell cultures and carries a chemical tag that cells recognize, so they pull it inside and deliver it to their lysosomes. There it takes over the breakdown work, which can halt further buildup and let some existing problems, such as an enlarged liver or spleen, improve. Each product replaces one specific enzyme, so ERT is a family of disease-specific treatments rather than a single drug. The infused enzyme is cleared from the body fairly quickly, so its effect fades between doses and treatment continues for life. It does not correct the underlying gene, and it is not a cure.

Who It's For

ERT is used for people diagnosed with a lysosomal storage disease that has an approved enzyme product. Examples include Gaucher disease (imiglucerase, sold as Cerezyme, which in 1995 became the first approved ERT), Fabry disease (agalsidase beta, sold as Fabrazyme, for people 2 years and older), Pompe disease (alglucosidase alfa, sold as Lumizyme, and avalglucosidase alfa, sold as Nexviazyme, for late-onset Pompe disease from age 1) and several types of mucopolysaccharidosis (MPS). The diagnosis is confirmed with enzyme and genetic testing before treatment, and newborn screening in some US states now finds some of these conditions in infancy. How well ERT fits depends on which organs the disease affects. Infused ERT cannot cross the blood-brain barrier, the lining that controls what passes from the bloodstream into the brain, so it does not treat the brain and nerve involvement that some forms cause. Cerezyme, for example, is approved only for the parts of Gaucher disease outside the brain. One exception is cerliponase alfa (Brineura), used to slow the loss of walking in children with CLN2 disease, a rare inherited brain disorder; it is delivered directly into the fluid spaces of the brain. Some conditions also have other options, such as oral medicines that reduce how much of the stored material the body makes, a stem cell transplant or clinical trials of gene therapy, and a specialist weighs these against ERT. The similar-sounding pancreatic enzyme replacement therapy is a different treatment: digestive enzyme capsules taken with meals when the pancreas does not make enough enzymes to digest food. This page covers infused ERT for inherited enzyme deficiencies.

What It Involves

Most ERT is given as an intravenous (IV) infusion, a slow drip into a vein, once a week or once every two weeks depending on the product. The dose is based on body weight, and an infusion usually takes one to several hours. Cerezyme, for instance, runs over 1 to 2 hours, while some other products are started at a slow rate and sped up as they are tolerated. Some people receive medicines beforehand, such as antihistamines, fever reducers or steroids, to lower the chance of a reaction. Treatment begins in a hospital or infusion center where staff are ready to manage allergic reactions. Once infusions have gone smoothly, many adults and children move to home infusions given by a nurse, as long as the clinical support to handle a reaction is in place. Brineura works differently: it is infused every other week through a small reservoir placed under the scalp that connects to the fluid spaces of the brain. Care is usually directed by a specialist in the disease, often at a genetics or metabolic center. Follow-up includes blood or urine tests that track the stored material, imaging of affected organs, heart, lung or kidney checks as the disease requires, and sometimes tests for antibodies against the enzyme.

What to Expect

ERT mainly works by stopping further buildup and giving affected organs a chance to recover where they can, so changes unfold over months and years rather than days. Organs that take up the enzyme readily, especially the liver and spleen, tend to respond best, and an enlarged liver or spleen often shrinks. Bones, cartilage and the eyes take up much less of the enzyme, so problems there respond less. In diseases that affect the heart or kidneys, the realistic goal is often to keep their function stable. Response varies widely between diseases and between people. Some people notice less nerve pain in Fabry disease or better walking and breathing in late-onset Pompe disease, while for others the main sign of success is that tests and organ measurements hold steady. Antibodies against the enzyme can weaken its effect in some people. Because of this, progress is judged by regular testing as much as by how someone feels, and the care team may adjust the dose based on results. Starting early tends to matter, particularly in infant-onset forms, because ERT protects tissue better than it repairs damage that is already established. The infusion schedule also becomes a regular part of life, with treatment every week or two for the long term.

What the Evidence Says

Because these diseases are rare, most enzyme products were approved on small studies, often without a placebo group, and their long-term effects are tracked through patient registries. Even so, some effects are large and clear. In infants with the most severe form of Pompe disease, 15 of 18 treated babies were alive without a breathing machine at 18 months of age, while only 1 of 61 untreated babies in an earlier comparison group was alive at all. Most treated infants still had substantially delayed motor development, a reminder that ERT changes the course of the disease without making it go away. In late-onset Pompe disease, a Cochrane review found that alglucosidase alfa probably improves the distance a person can walk in six minutes by about 30 meters and modestly improves lung capacity compared with placebo over 78 weeks. That conclusion rests on a single trial of 90 people, and effects on longer-term outcomes, such as needing a wheelchair or breathing support, remain uncertain. Across lysosomal storage diseases, reviews report smaller liver and spleen size, steadier heart and kidney function and less nerve pain, with results depending on the disease, how advanced it is and which organs are involved. The evidence is weakest for brain and bone involvement, which infused ERT reaches poorly. Newer versions of these enzymes aim to improve delivery, but none is a cure.

Risks & Considerations

Reactions during or shortly after an infusion are the most common problem. Studies report allergic-type reactions in up to about 1 in 5 people receiving ERT, usually mild: itching, flushing, hives, rash, chills, fever or chest discomfort. Slowing or pausing the infusion and giving antihistamines or steroids usually controls them. People who keep reacting can sometimes continue through desensitization, in which the dose is reintroduced in small, gradually increasing steps under close supervision. Labels for these products, including Cerezyme and Lumizyme, carry a boxed warning, the most prominent warning the US Food and Drug Administration puts on a label, about severe allergic reactions including anaphylaxis. These can happen with early doses and also after months or years of uneventful treatment, which is why treatment starts in a monitored setting. During or after a home infusion, trouble breathing, swelling of the face, lips or throat, or feeling faint is an emergency: call 911. Over time the immune system can make antibodies against the replacement enzyme. These can raise the chance of reactions and, in some people, make the treatment less effective. This is a particular concern for some infants with Pompe disease, who may need added treatment to calm the immune response. Some individual products carry further specific warnings, so it is worth asking which apply to the one being used. The practical burden is real: infusions every week or two for life, time away from school or work, repeated needle access to a vein and a very high cost that makes insurance approval and specialty pharmacy coordination part of treatment.

Questions to Ask Your Doctor

  1. 1.Which parts of this condition can ERT help, and which, such as brain or bone involvement, is it unlikely to reach?
  2. 2.Are there alternatives, such as an oral medicine, a transplant or a clinical trial, and how do they compare with ERT?
  3. 3.How often will infusions be, how long will each one take, and could they eventually be given at home?
  4. 4.Which tests will show whether the treatment is working, and how often will they be done?
  5. 5.What reactions should we watch for, what is the plan if one happens, and will antibody levels be checked?

Last reviewed • Oct 2026

Educational content, not medical advice.